Sudarshan Pharma Industries Management Change

Fund RaiseAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

Financial ResultsAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sudarshan Pharma Industries Q2 FY27 Results: Net Profit ₹8.1 Cr, Up 92.9% YoY

Sudarshan Pharma Industries Ltd reported revenue from operations of ₹217 Cr (+28.5% YoY) and net profit of ₹8.1 Cr (+92.9% YoY) for Q2 FY27.

Key figure

Net profit ₹8.1 Cr · +92.9% YoY

Board Meeting DateAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sudarshan Pharma Industries Board Meeting Date

Sudarshan Pharma's board meets 29 October 2026 to consider Q2 results and a fund-raising proposal. Trading window remains closed until 48 hours after results.

SME to Main Board MigrationAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sudarshan Pharma Industries SME to Main Board Migration

Sudarshan Pharma's shares will list on NSE's main board from October 27, 2026, migrating from BSE SME. Trading begins under symbol SUDARSHAN, marking a platform upgrade.

Other Announcement

Sudarshan Pharma Industries Other Announcement

Sudarshan Pharma Industries Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.

Merger & Restructuring

Sudarshan Pharma Industries Merger & Restructuring

Sudarshan Pharma terminated its proposal to acquire 9.50% of Med Therapy Biotechnology Inc. The promoters' parallel 1.50% each acquisition plan also stands terminated.

Management ChangeLife Insurance Corporation of India LICI

Life Insurance Corporation of India Management Change

LIC announced superannuation of four Senior Management Personnel w.e.f. October 31, 2026. All four Executive Directors and one Zonal Manager will be relieved by close of office on October 30, 2026.

Management ChangeKaira Can Company Ltd KAIRA

Kaira Can Company Management Change

Kaira Can Company appointed Mr. Bharat A. Kapadia as Additional Director (Non-Executive, Non-Independent) effective 30 October 2026. The appointment brings his business-development experience to the board.

Management ChangeIntellect Design Arena Ltd INTELLECT

Intellect Design Arena Management Change

Intellect Design Arena appointed Suresh Eshwara Prabhala as Non-Executive Independent Director for a 60-month term. The board meeting approving this was held on 30 October 2026.

Management ChangeWestern Overseas Study Abroad Ltd 544636

Western Overseas Study Abroad Management Change

Western Overseas Study Abroad Ltd disclosed that Non-Executive Director Mr. Deepak Kumar resigned effective 30 October 2026. The board will note the resignation, citing other work commitments.

Management ChangeDivgi Torqtransfer Systems Ltd DIVGIITTS

Divgi Torqtransfer Systems Management Change

Divgi TorqTransfer Systems appointed Mr. Sarang Deshpande as Company Secretary and Compliance Officer. Ms. Ishita Kokare resigned that role effective October 30, 2026.

Management ChangeReligare Enterprises Ltd RELIGARE

Religare Enterprises Management Change

Religare Enterprises appointed Ms. Dipti Jayesh Khandelwal as Company Secretary and Compliance Officer w.e.f. October 31, 2026. She was designated as a Key Managerial Personnel.